Purpose: To carry out economic evaluation of antibacterial usage for Ear, Nose and Throat infections in a tertiary health care facility in Nigeria. Methods: Antibacterial utilisation evaluation was carried out retrospectively over one year period by reviewing 122 case notes containing 182 prescriptions of patient with Ear Nose and Throat infections.
Introduction
Drug utilization review is one of the conceptual models for effective use of drugs [1] , particularly if cost evaluation is included. In most developing countries, regulatory capacity is very weak, most laboratories are poorly equipped and researches are poorly funded. Institutionally organized drug utilization evaluation does not exist in most hospitals as well. In most of these countries, important data on antibacterial usage for sound policy and formidable decisions remain scarce.
"Community-acquired respiratory tract infections (RTIs) including bacterial sinusitis, acute otitis media, acute exacerbations of chronic bronchitis and community acquired pneumonia (CAP) are among the most frequent infections treated by physicians and represent a major international health problem" [2] . It has been reported that about 10% of the worldwide burden of morbidity and mortality relates to RTIs [3] . Whilst the majority of this is viral in aetiology, three quarter of all antibiotic consumption is for RTIs [3] . Ongoing threat of antibacterial resistance coupled with irrational use by the public and some health care professionals and poor surveillance activities in most developing countries are indeed compelling reasons for concern.
Infectious diseases have the greatest impact on human being because of their externality. Non affordability of quality therapy by infected patients has serious implications on the health and wealth of the nation. Delay or non-treatment leads to complications, increase cost, increase morbidity and mortality and spread due to communicable nature. Inadequate or inappropriate treatment equally leads to development of resistance in addition. World Health Organization (WHO) in 2006 also pointed out that one-third of the global population has no access to good quality Medicines [5] . Therefore, any useful intervention that can encourage accessibility and affordability will go along way particularly in poor countries like Sub-Sahara Africa where dropping out of therapy due to cost has been reported [4] . In today's competitive, limited-resource healthcare environment, choices and trade offs in providing healthcare services are inevitable. In developing countries, the cost of healthcare is prohibitive and borne mostly from out of pocket expenses. Economic evaluation is increasingly being advocated even in developed countries [6, 7] , but this is inadequately so in Nigeria among other African countries where available resources for healthcare are much more limited. Previously, emphasis has been basically on clinical outcomes of therapy with little critical consideration for economic and psychosocial outcomes [8, 9] . Evidence-based cost related studies are very rare in Nigeria and among other developing countries for accurate health budget planning and reliable policy making the studies imperative. The objective of the study was to carry out economic evaluation of antibacterial usage for Ear, Nose and Throat infections in the chosen tertiary health care facility.
Methods

Setting
The study was carried out in the 764-bed Lagos University Teaching Hospital (LUTH), Nigeria which is a tertiary health care centre. The hospital comprises Accident and Emergency Unit as well as In-patient and General Out-Patient units including Ear, Nose and Throat (ENT) clinic. Total patient turnover in the hospital is about 10,000 monthly. Various specialties and wards as well as diagnostic facilities, typical of teaching hospitals, are in place. Antibacterial agents, if indicated, are prescribed in all the departments for surgical and medical cases. The personnel involved are as typical of any teaching hospital comprising the consultants, resident doctors, pharmacists, medical laboratory scientists among others. Each of the hospital department has a pharmacy unit attached.
Study design
This was a retrospective drug utilization evaluation involving the use of randomly selected 525 out-patient case notes for three categories of disease conditions that has antibacterial agents as the mainstay of therapy. This sample exceeded the calculated 384 case notes using standard statistical procedure. The period covered the year 2005 to 2006. Out of the randomly selected case notes, the entire 122 containing 182 prescriptions for Ear, Nose and Throat Infections were examined. The systematic randomised sampling was facilitated with the aid of diagnostic coding cards. All age groups of relevant out-patients with antibiotic prescription(s) were included in the study.
Data collection
Relevant data such as date of visit, demographics, diagnosis, type of diagnostic test, prescribed drugs, and dosages, frequency of dosing and duration of therapy were extracted using an appropriately designed and validated data collection forms. Follow-up visit if any, and test of cure (a repeat diagnostic test within a month of therapy to ascertain complete eradication of infection or otherwise) were also collected.
Outcome measures
The surrogate clinical outcome measure determined included hospital visits, type of diagnostic tests and respective proportion of patients involved, test of cure and isolated organisms. Others were volume (in doses), type and class of antibacterial agents prescribed and appropria-teness. Also considered was whether the prescription was in generic or branded names. Economic outcomes included the cost per defined daily dosage of each agents (C/DDD) [10] , antibacterial cost per visit for each patient and cost of each class of antibacterial agent. Others were average cost per dose of antibacterial agent, average cost of antibacterial agents per patient. There was no adjustment for discounting and inflation in cost determination as all the costs occurred within one year of data collection. However, the exchange rate of the local currency (naira, N) to the US dollar (US$) at the time of analysis was used to allow for consistency.
Data Analysis
The collected data were analysed using Epi Info (CDC, 2002). Mean cost per defined daily dose (C/DDD) and the total cost of antibacterial agents per visit for each patient were computed for each drugs. Defined daily dose has been recommended for cost analysis of drugs [10] . Also determined were the proportions of prescriptions in generic and branded names, the cost for each class of antibacterial agents, and number of visits. The volume of usage in doses for each drug and respective class of antibacterial agents were also computed. Proportional data were analysed using chi square test and Fisher's exact test (for small numbers) while mean costs were compared using Student T test. Descriptive statistics (means and percentages) were used in the presentation of results. At 95% confidence interval, a 2-tailed pvalue less than 0.05 was considered significant.
Results
Demographic Data and Hospital Visit
Disease occurrence was significantly higher among children of age group 0-10 years (59.3%) when compared to any other age group (p<0.05). There was no significant difference between male (57.7%) and female (42.3%) patients (p<0.05). Follow-up visits to the hospital by patients (33.0%) was significantly lower than first visits (67.0%) by patients (p<0.05) ( Tables 1 and 2 ). 
Clinical variables
Otitis media was the most prevalent and occurred among 82 (45.0%) patients. Acute and chronic suppurative otitis media occurred in 45 (24.7%) and 37 (20.3%) of the patients respectively. This was followed by bronchopneumonia which occurred among 70 (38.5%) patients. Treatments were largely empirical and there were documented cases of microscopy culture and sensitivity (m/c/s) test in 14 (7.7%) patients.
Drug indicator variables
The total number of drugs prescribed in generic names were 95 (34.1%) which is significantly lower than those prescribed in brand names 180 (65.9%) (p<0.05). Average number of drugs per prescription was 1.5 and the volume of antibacterial agent prescribed in doses was 5571 doses. Penicillins, the most frequently prescribed shares 35.5% of the total prescriptions (Table 3) .
Cost variables
The total antibacterial cost was N358,760.00 (US$2759.92) with an average cost per case of N1971.37 (US$15.16) and average cost per dose of N64.40 (US$0.49). Penicillins shares N89,468.00 (US$688.22) representing 24.9% of the total antibacterial cost. Cephalosporins which were prescribed in 12.1% of the cases had the largest antibacterial share cost of N173,554.00 (US$1335.03), with a cost proportion of 48.4%. Average antibacterial cost for otitis media was N825.00(US$6.35) while that of bronchopneumonia was N3675.41±1207.58 (US$28.27 ±9.28) ( Table 4) . 
Discussion
Otitis media which was the most prevalent in almost half of the patient, has been previously reported as the commonest Ear, Nose and Throat infection with a prevalence rate of 14.7% in children 0-12 years and 29.0% in children 0-5 years of age in South-Western Nigeria [11] . With a population of about 140 million [12] , 29.0% in children below 5 years (who normally constitute 20.0% of total population) implies about 7.7 million cases in Nigeria. Majority of the affected children usually belong to low socio economic group who can hardly afford basic health care as a result of an association between infections, poor sanitary conditions and low standard of living. Most Nigerians (70.2%) have been reported to be living below the poverty line earning less than US$1 per day even before global economic should be enhanced capacity building and facility provision to promote rapid diagnosis. Provision of regularly up-dated evidence-based treatment guidelines, data base on antibacterial resistance and sustainable surveillance activities, to guide empiric therapy are also necessary.
The antibacterial agents were rationally prescribed but largely empirical. Antibacterial susceptibility testing in seven percent of cases reviewed is very low. Empirical antibacterial therapy is a major factor in the development of antibacterial resistance [13, 14] . However, empiric therapy is somewhat inevitable in Nigeria due to poor diagnostic facilities and poverty among many patients who may not be able to afford quality health care services. Over the counter prescription of antibacterial agents even by quacks, in effective drug distribution system, weak regulations and poor surveillance activities are other factors seriously threatening antibacterial therapy success in Nigeria and other developing countries. It is important to address these by all the stakeholders urgently.
More than two-third of prescriptions were in branded names instead of generic (p<0.05) in contrary to recommendations of National Drug Policy of 2005 [15] . Lack of adequate awareness on the implications may be responsible. It makes patients to think that generic products are inferior; hence societies including poor teaming masses are tactically being forced to spend more in buying the branded products. However, lack of trust as regard the quality of some generic products might be a factor. Generic prescription should be encouraged particularly for developing countries where health spending per capita is about US$15.00 -US$21.00 annually, unlike developed countries where per capita health spending is about US$2000.00 [16] . Quality control of generics should be strengthened and evidence of efficacy ascertained periodically.
The most widely prescribed class of drug was the penicillins at a frequency of 35%, at a cost of N89,468.00 (US$688.22) representing 24.9% of total antibacterial cost for all agents. This observation is in agreement with previous reports [17] . Cephalosporins were second to the penicillins at a prescribing rate of 12.1% but with a whopping cost of N173,554 (US$1335.03) which represents about half of the total antibacterial cost. Out of the 12.1%, cefuroxime alone constitutes 10.1% but only 16.7% of the huge cost. This is probably because of its availability in oral formulations in addition to injection.
The cost proportions of co-amoxiclav among the penicillins and other cephlosporins apart from cefuroxime indicates that usually few drugs are responsible for high total cost of antibacterial therapy. Their usage should be monitored and cost effectiveness analysis carried out on regular basis to monitor their use and optimise therapy.
Conclusion
Antibacterial cost to patients and by extension the nation at large is enormous and a greater proportion of the antibacterial cost is due to few agents. This call for prudent use of these agents which should be evidence based and closely monitored.
